Form 4: Boston Scientific EVP and CFO Daniel J. Brennan Executes Stock Options and Sells Shares

Daniel J. Brennan, EVP and CFO of Boston Scientific, exercised stock options and sold shares of common stock on February 11th and 12th, 2025, according to a Form 4 filing with the SEC.

Summary

• Daniel J. Brennan, the EVP and CFO of Boston Scientific, engaged in transactions involving the company's stock.
• On February 11, 2025, Brennan acquired 33,944 shares of common stock at $0.00 and disposed of 16,414 shares at $105.98.
• On February 12, 2025, Brennan exercised options to acquire 15,087 shares at $16.31 and sold 15,087 shares at a weighted average price of $105.0663.
• These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024.
• Following these transactions, Brennan directly owns 241,451 shares of Boston Scientific common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions are part of a pre-planned trading strategy and don't necessarily reflect a change in the executive's confidence in the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.

Comparison to Industry Standards

• Executive compensation packages often include stock options and performance-based share units, aligning management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a standard practice among corporate executives to manage their stock transactions in a transparent and compliant manner.
• Comparing Brennan's stock ownership and trading activity to those of CFOs at comparable medical device companies (e.g., Medtronic, Abbott, Stryker) could provide insights into industry norms.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are routine and pre-planned.
• Shareholders may be interested in the trading activity of key executives as an indicator of management's sentiment, but these transactions are unlikely to be significant.

Key Dates